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Introduction: Gelatinous Heberden’s nodes (HNs), also termed synovial cysts, are a common form of generalized
osteoarthritis (OA). We sought to determine whether HN cases at clinical presentation contained multipotential
stromal cells (MSCs) and to explore whether such cells were more closely related to bone marrow (BM) or synovial
fluid (SF) MSCs by transcriptional analysis.
Methods: At clinical presentation, gelatinous material was extracted/extruded from the distal phalangeal joint of
OA patients with HNs. From this, plastic adherent cells were culture-expanded for phenotypic and functional
characterization and comparison with BM- and SF-MSCs. Mesenchymal related gene expression was studied by
using a custom-designed TaqMan Low Density Array to determine transcriptional similarities between different MSC
groups and skin fibroblasts.
Results: In all cases, HN material produced MSC-like colonies. Adherent cultures displayed an MSC phenotype
(CD29+, CD44+, CD73+, CD81+, and CD90+ and CD14− CD19−, CD31−, CD34−, CD45−, and HLADR−) and exhibited
osteogenic, chondrogenic lineage differentiation but weak adipogenesis. Gene cluster analysis showed that
HN-MSCs were more closely related to SF- than normal or OA BM-MSCs with significantly higher expression of
synovium-related gene markers such as bone morphogenic protein 4 (BMP4), bone morphogenetic protein receptor
type 1A (BMPR1A), protein/leucine-rich end leucine-rich repeat protein (PRELP), secreted frizzled-related protein 4
(SFRP4), and tumor necrosis factor alpha-induced protein 6 (TNFAIP6) (P <0.05).
Conclusions: Gelatinous HNs derived from hand OA at clinical presentation contain a population of MSCs that
share transcriptional similarities with SF-derived MSCs. Their aberrant entrapment within the synovial cysts may
impact on their normal role in joint homeostasis.Introduction
Osteoarthritis (OA) represents a common age-related di-
sease characterized by progressive joint destruction, loss
of function, and joint failure. Decompensated joint re-
modeling with florid new bone formation is also a feature
of advanced OA, and generalized nodal OA represents a
striking example of this bone-forming phenotype. Nodal
OA may present acutely with painful joint swelling or* Correspondence: d.g.mcgonagle@leeds.ac.uk
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(HNs), which subsequently are associated with ossifi-
cation and radiographic features of OA [1,2]. As such,
HNs are seen as predictors of osteophyte formation,
cartilage loss, and joint space narrowing [3,4].
Skeletal repair, remodeling, and new bone formation
are thought to be linked to multipotential stromal cell
(MSC) function, whereby highly proliferative cells from
a variety of sources (such as bone marrow (BM), syno-
vium, and adipose tissue) can form mesenchymal lineage
tissues [5]. Consequently, substantial academic and in-
dustrial investment has focused on determining the role
of MSCs in OA pathology and the potential of MSC-
based therapy to treat advancing disease, and 28 clinicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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“mesenchymal stem cells” AND “osteoarthritis” [6]).
We originally identified a population of MSCs in knee
synovial fluid (SF) and observed their increase in early
knee OA [7]; similarly, increases are also reported follo-
wing joint injury [8,9]. It is speculated that mobilization
of MSCs from the synovium into the SF is a response to
tissue injury, suggesting that SF-MSCs play a role in
joint homeostasis [9,10]. There is also good evidence
that, under a corrected mechanical environment, using
joint distraction, cartilage regeneration can be achieved
without direct manipulation of the synovial compart-
ment [11,12], again suggesting that the joint has the in-
trinsic capacity to restore and remodel OA-associated
pathology [13]. Given that HNs are associated with new
bone formation and that the constituents of the gelatin-
ous material are similar to SF [2,14], we hypothesized
whether HN cysts contain a population of MSCs similar
to those found in other synovial joints.
Although ossified HNs are common, early manifesta-
tions with gelatinous material are infrequent and rarely
present to the clinician at a stage when they can be aspi-
rated [1,2]. We undertook cellular and transcriptional
evaluation of culture-expanded cells from patients with
gelatinous HNs at clinical presentation and compared
those cells with MSCs derived from OA SF and BM
from OA and normal patients. Herein, we show that
such patients with early HNs have an MSC population
entrapped within these cysts.
Methods
Collection of gelatinous material from Heberden’s nodes
We identified three female patients (ages 44 to 66 years)
with painful distal interphalangeal (DIP) joint HNs. All
imaging and samples were collected following informed
written consent under ethics approved by the Leeds EastFigure 1 Sample collection, cell growth, and multipotential stromal c
and an acute Heberden’s node (HN) with extrusion of gelatinous material a
indicating preservation of articular cartilage at clinical presentation. (B) Exam
cyst material and (C) population doublings of HN cells between passages 0
multipotential stromal cells. BM, bone marrow.NHS Research Ethics Committee. Patients had conven-
tional x-ray of their hands prior to sample collection
(Figure 1A). HNs were punctured aseptically with a 16-
guage needle; gelatinous material within was extruded
from the joint (Figure 1A) and collected in 5 mL of saline.
Cell isolation and culture expansion
Extruded HN material was diluted (1:4) with non-
hematopoetic (NH) expansion medium (Miltenyi Biotec,
Bisley, UK), centrifuged, and resuspended in NH medium.
Samples were plated in triplicate and cultured for 14 days
with twice-weekly media changes in NH medium before
counting colonies; these cells were considered passage 0
(p0). Thereafter, colonies were trypsinised (0.25% trypsin;
Invitrogen, Paisley, UK) and further expanded. For expan-
sion, cells were seeded at a density of 104 cells per cm2,
with twice-weekly media changes, and further grown to
between p1 and p3.
For comparative analysis, MSCs were also expanded
from OA knee SF aspirates as described above for HN
cells (SF, n = 5 donors) and normal and OA BM. Briefly,
normal iliac crest BM (ICBM) (n = 11) was aspirated
from orthopedic patients undergoing elective surgery
for the removal of metalwork. BM from OA patients—
osteoarthritic femoral canal BM (OAFCBM) (n = 3)—was
aspirated from the medullary canal at the neck of the
femur during hip arthroplasty [15]. Plastic adherent cells
from normal and OA BM were expanded as for NH cells.
Additionally, MSCs were isolated from osteoarthritic fe-
moral head BM (OAFHBM) (n = 3). Femoral heads from
hip arthroplasty of patients with OA were mined by using
a bone mill. Bone fragments were washed in phosphate-
buffered saline, and cells were enzymatically extracted
with collagenase as previously described [16]. For eth-
ical reasons, BM could not be collected from the iliac
crest of patients with OA. Patients were between 39ell characterization. (A) Distal interphalangeal joint with osteoarthritis
nd plane radiograph demonstrating visible joint space (arrowhead)
ple of multipotential stromal cell-like colony grown from gelatinous
and 1 compared with synovial fluid (SF)- and iliac crest bone marrow-
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as above. Primary fibroblast (FB) lines CRL-2068 and
HFF1 (ATCC, Teddington, UK) and NHDF (Lonza, Basel,
Switzerland) were purchased and grown similarly. Growth
kinetics for HN cells was compared with SF- and ICBM-
MSCs by calculating the population doubling rate (PDR)
between p0 and p1 by using the following equation:
PDR = days in culture/population doubling (PD), where
PD = log2x(log cells harvested/log cells seeded).
Trilineage differentiation
Trilineage differentiation assays were performed as pre-
viously described [17]. Briefly, cells (2.5 × 105) were pel-
leted and cultured in chondrogenic medium for 21 days
(reagents and methods as defined in [18]). For histology,
pellets were embedded in paraffin and 8-μm sections
were stained with 1% toluidine blue (Sigma-Aldrich,
Gillingham, UK). For osteogenic and adipogenic diffe-
rentiation, cells were plated in six-well plates at a densi-
ty of 103 cells per cm2 and cultured for 21 days in either
osteogenic or adipogenic differentiation media [18]; cells
were stained with alizarin red and oil red O, respectively.
Phenotypic analysis by flow cytometry
Flow cytometry was performed by using an LSRII four-
laser flow cytometer (BD Biosciences, Oxford, UK) with
appropriate isotype controls. Passaged MSCs (p3 from
HN, SF, and ICBM) (n = 3 for each group) were stained
with combinations of the following antibodies at the di-
lution recommended by the manufacturers: anti-CD14-
allophycocyanin-cyanine (APC-H7), anti-CD19-fluorescein
isothiocyanate (FITC), anti-CD34-peridinin chlorophyll
protein (PerCP), anti-HLADR-phycoerythrin-cyanine
(PE-Cy7), anti-CD73-phycoerythrin (PE), anti-CD90-PE,
anti-CD81-FITC, anti-CD44-FITC, and anti-CD29-FITC
(all from BD Biosciences). Cells were stained with 4′,6-
diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) as a
live/dead discriminator immediately prior to acquisition
[15]. At least 10,000 live cell events were collected for
each antibody combination.
Quantitative real-time polymerase chain reaction
RNA was isolated from p1- to p3-expanded MSCs from
HN, SF, OAFCBM, OAFHBM, ICBM, and primary FBs
(n = 3 for each group) by using the Norgen Biotec RNA/
DNA/protein kit (Geneflow, Lichfield, UK) in accord-
ance with the instructions of the manufacturer. RNA
was reverse-transcribed by using the High Capacity
cDNA reverse transcription kit for use on a 96-gene
custom designed TaqMan Low Density Array (Applied
Biosystems, Warrington, UK). Based on recommenda-
tions of the manufacturer, 200 ng cDNA was used per
port (two ports per sample). Analysis used the 2(−ΔCt)
method, normalized to the reference gene HPRT1 [19].Hierarchical cluster analysis of quantitative polymerase
chain reaction (qPCR) data was log2-transformed and
filtered (filter = 80% present), resulting in 88 out of 96
genes analyzed. Complete linkage analysis was performed
and dendrograms were generated by using Cluster 3.0
software and Java TreeView version 1.1.6 [19,20]. Statis-
tical analysis (Mann-Whitney U) was performed by using
SPSS 20 (IBM Inc., Portsmouth, UK).Results
Gelatinous material from Heberden’s node contains
multipotential stromal cell-like cells
Similar to control SF and ICBM [17], MSC-like cells
were isolated and expanded from the gelatinous material
from the DIP joint HNs of all three patients (Figure 1A
and B). After 14 days of proliferation and from approxi-
mately 0.5 mL of gelatinous material, four, 16, and 42
colonies were present from the three patient samples.
With further expansion after p0, HN cells continued to
grow at rates similar to SF- and ICBM-derived MSCs
(Figure 1C). Each HN culture was taken to at least p2,
corresponding to approximately 15 to 20 population
doublings (PDs). This was equivalent to approximately 1
PD every two days, consistent with our previously re-
ported results for SF- and ICBM-MSCs [7].Trilineage potential of Heberden’s node cells
Trilineage differentiation was performed on culture-
expanded (p2-3) cells (Figure 2A). Pellets formed in chon-
drogenic medium stained positive for sulphated-GAGs,
consistent with SF and ICBM controls and indicative
of progression toward the chondrogenic lineage. HN
cells cultured in osteogenic medium exhibited strong
alizarin red staining, similar to SF-derived MSCs but
less than those derived from ICBM, indicating that
cells were committed to an osteogenic lineage. In con-
trast to SF- and ICBM-MSCs, all HN samples tested
demonstrated weak staining for adipogenesis, with only
isolated cells having an accumulation of micro-vesicles
(Figure 2A).Culture-expanded cells from Heberden’s node have a
multipotential stromal cell phenotype
Flow cytometry was used to determine the immuno-
phenotype of expanded HN cells and compared with
SF- and ICBM-derived MSCs. HN cells were uniformly
negative for CD14, CD19, CD31, CD34, CD45, and
HLADR (Figure 2B). Consistent with an MSC pheno-
type, HN cells were uniformly positive for CD29, CD44,
CD73, CD81, and CD90 (Figure 2B). This immunophy-
notype was similar to culture-expanded SF- and ICBM-
MSCs.
Figure 2 Multipotential stromal cell (MSC) differentiation and immunophenotyping. (A) Representative images show trilineage
differentiation capacity of Heberden’s node (HN)-MSCs compared with synovial fluid (SF)- and iliac crest bone marrow (ICBM)-MSCs.
Adipogenesis of HN-MSC was low, and only micro-vesicles were observed (insert). (B) Plot showing mean percentage of populations
positive for cell surface markers by flow cytometry (n = 3 for HN-, SF- and ICBM-MSCs). Error bars represent standard deviation. Below are
example histogram overlays of Heberden’s node (blue), synovial fluid (green), and bone marrow (red) MSCs with isotype control
(grey-filled).
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Figure 3 Differential gene expression analysis. Hierarchical
cluster analysis of quantitative polymerase chain reaction data from
culture-expanded Heberden’s node, synovial fluid, osteoarthritic
femoral canal bone marrow, osteoarthritic femoral head bone
marrow, and normal iliac crest bone marrow-derived multipotential
stromal cells together with fibroblasts. Expression levels are normalized
to HPRT1, where black is 1, red is greater than 1, green is less than 1,
and grey is below detection.
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Heberden’s node-MSC are transcriptionally related to
synovial fluid-MSC
To further characterize HN-MSCs, qPCR was performed
by using transcripts that reflect the stromal origin and
trilineage potential of MSCs [19]. Hierarchical cluster
analysis was used to determine similarities in expression
patterns between HN-, SF-, OAFCBM-, and OAFHBM-
MSCs (all from patients with established OA) as well as
MSCs from normal ICBM and primary FBs (Figure 3).
MSCs derived from OA patient BM were used to control
for potential differences in expression patterns between
normal and OA BM. All MSC samples clustered away
from FBs on a separate branch, confirming that gene
expression profiles were cell type-specific (for MSCs).
HN-MSCs clustered together with SF-MSCs, whereas
all BM-derived MSCs clustered as a distinct group away
from SF- and HN-MSCs (Figure 3). This clustering of
SF- and HN-MSCs shows a similar transcriptional profile,
indicating that these cells may share a common niche-
specific origin and that the expressions of these genes
were not related to OA.
Examples of differentially expressed genes between
MSCs and FBs are shown in Figure 4A and Table 1.
These data confirmed ICBM-MSC specificity for these
genes as reported in our previous study [19] and ex-
tend this to SF- and HN-MSCs, suggesting MSC
specificity for these genes regardless of the tissue of
origin. Additionally, we identified genes differentially
expressed between MSCs from the joint and BM
(Figure 4B and Table 2). Significantly, a common niche
identity for both HN- and SF-MSCs was clearly seen
within this set of genes as increased expression of tran-
scripts known to be associated with synovial MSCs,
such as bone morphogenic protein 4 (BMP4), bone
morphogenic protein receptor type 1A (BMPR1A),
protein/leucine-rich end leucine-rich repeat protein
(PRELP), secreted frizzled related protein 4 (SFRP4),
and tumor necrosis factor α-induced protein 6
(TNFAIP6) [9,21-23].
Our data also identified increases in the expression of
genes associated with chondrogenesis for both HN- and
SF-MSCs over BM-derived MSCs (Figure 4B and Table 2),
including aggrecan (ACAN): bone morphogenetic protein
Figure 4 Examples of differentially expressed genes. (A) Relative expression levels of genes differentially expressed between all multipotential
stromal cells (MSCs) and fibroblasts (FBs). (B) Relative expression of differentially expressed gene between Heberden’s node (HN)- and synovial
fluid (SF)-MSCs compared with bone and bone marrow-derived MSCs from normal and osteoarthritis patients. All cell types were tested in
triplicate. OAFCBM, osteoarthritic femoral canal bone marrow; OAFHBM, osteoarthritic femoral head bone marrow.
Baboolal et al. Arthritis Research & Therapy 2014, 16:R119 Page 6 of 10
http://arthritis-research.com/content/16/3/R1194 (BMP4) and cartilage oligomeric matrix protein (COMP)
[22,24]. Taken together, these data indicated a potential
common origin/synovial niche specificity for HN- and
SF-MSCs.
Discussion
Acute HNs are a feature of pre-radiographic hand OA
and these gelatinous synovial cysts are thought to be a
forerunner of new bone formation [1-4]. The nature of
the gelatinous material (being rich in hyaluronan [2,14])
and the new bone formation that occurs in OA at these
locations lead us to the hypothesis that MSCs may be-
come entrapped from the joint SF in such material in
the earliest stages of OA. Herein, we show the presence
of HN resident cells which met functional, phenotypic,
and transcriptional profiles of MSCs that are closely re-
lated to SF-MSCs [9,19].
Although HNs are a common form of generalized
nodal OA, clinical presentation at the acute phase, prior
to ossification, is somewhat rare; only three cases haveappeared in our clinic in the past five years [1,3]. Con-
sequently, only a small number of such gelatinous cysts
could be sampled. Despite these low sample numbers,
the functional, phenotypic, and transcriptional data pre-
sented here are consistent with these cells being MSCs.
There was, however, a surprising difference in the ca-
pacity of the HN-MSCs to differentiate toward the adi-
pogenic lineage. Functional assays showed only isolated
cells with the accumulation of micro-vesicles in each do-
nor, despite the expression of the adipogenic transcrip-
tion factors CEBPA (CCAAT/enhancer-binding protein)
and PPRAG. A lack of adiopogenesis has been linked to
‘in vitro’ aging of MSCs, whereby the ability of cells to
differentiate is reduced as the cells approach senescence
[25,26]. Owing to the prolonged culture expansion per-
iod needed to expand HN-MSCs to sufficient numbers
to complete our functional, phenotypic, and expression
assays, our cells may have been approaching senescence,
which has reduced their capacity to differentiate toward
the adipogenic lineage.
Table 1 Common multipotential stromal cell genes
Fold changing in expression between:
Gene HN/FB SF/FB ICBM/FB
ACVR2A Activin A receptor, type IB 2.8 3.5 7.0
ANGPT1 Angiopoietin 1 5.3 4.6 4.9
BAMBI Bone morphagenietic protein and activin membrane-bound inhibitor homolog 18.2 36.8 10.2
CDH11 Cadherin 11 11.4 8.8 9.0
COL1A1 Collagen, type I, alpha 1 15.3 4.3 6.0
COL1A2 Collagen, type I, alpha 2 20.2 20.8 9.9
CXCL12 Chemokine ligand 12 3.1 5.4 1.9
EPHB4 Ephrin receptor B4 5.5 2.3 2.6
FZD1 Frizzled family receptor 1 4.7 11.5 4.6
GDF5a Growth differentiation factor 5 73.5 4.04 25.5
GJA1 Gap junction protein, alpha 1 8.2 14.7 10.2
HAPLN1a Hyaluronan and proteoglycan link protein 1 397.3 258.5 691.3
IGFBP3 Insulin-like growth factor-binding protein 3 59.5 107.8 5.1
MYH9a Myosin heavy chain 9 6.0 6.0 6.8
PAPSS2 3′-phosphoadenosine 5′-phosphosulfate synthase 2 2.8 5.1 2.7
RUNX1 Runt-related transcription factor 1 3.0 59.0 1.9
SFRP4 Secreted frizzled-related protein 4 171.2 908.9 4.8
SORT1 Sortilin 1 4.4 8.9 11.1
SPARC Secreted protein, acidic, cysteine-rich 7.0 7.0 7.1
VEGFC Vascular endothelial growth factor C 3.1 10.2 1.6
Relative fold change in expression compared with fibroblasts (FBs) (P ≤0.05, Mann-Whitney U). aNewly identified genes. HN, Heberden’s node; ICBM, normal iliac
crest bone marrow; SF, synovial fluid.
Table 2 Tissue-specific multipotential stromal cell genes
Fold changing in expression between:
Gene HN/ICBM SF/ICBM HN/SF
ACAN Aggrecan 12.5 15.6 0.8
ALPL Alkaline phosphatase 4.8 6.4 0.8
BMP2 Bone morphogenetic protein 2 3.1 20.8 0.1
BMP4 Bone morphogenetic protein 4 3.2 5.6 0.6
BMPR1A Bone morphogenetic protein receptor, type IA 3.8 4.3 0.9
CEBPA CCAAT/enhancer-binding protein 11.4 19.1 0.6
COMP Cartilage oligomeric matrix protein 17.2 10.8 1.6
DAAM2 Disheveled associated activator of morphogenesis 2 2.9 2.2 1.4
FZD4 Frizzled family receptor 4 13.4 7.5 1.8
GATA2 GATA-binding protein 2 7.1 9.4 0.7
IGFBP3 Insulin-like growth factor-binding protein 3 11.8 21.3 0.6
OMD Osteomodulin 7.8 32.0 0.2
PPARG Peroxisome proliferator-activated receptor gamma 79.9 14.0 5.7
PRELP Proline/arginine-rich end leucine-rich repeat protein 19.1 87.1 0.2
SFRP4 Secreted frizzled-related protein 4 35.7 189.6 0.2
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 33.4 97.8 0.3
UGDH Uridine diphosphoglucose dehydrogenase 2.1 3.1 0.7
Relative fold change in expression identified as diagnostic for synovial fluid/Heberden’s node-multipotential stromal cells (SF/HN-MSCs) from statistical analysis
(P ≤0.05, Mann-Whitney U). ICBM, normal iliac crest bone marrow.
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shown to reliably distinguish MSCs from FBs and sub-
divide MSCs from their tissue of origin by identifying
commonly expressed genes when cells are grown under
the same conditions [27-30]. Here, we used a similar ex-
perimental approach and confirm our previous findings
[19], indicating mesenchymal lineage-specific expression
of genes on our custom array (Table 1). We verified that
FZD1 (frizzled family receptor 1), IGFBP3 (insulin-like
growth factor-binding protein 3), PAPSS2 (3′-phosphoa-
denosine 5′-phosphosulfate synthase 2), and VEGFC
(vascular endothelial growth factor C) are differentially
expressed between MSCs and FBs [30] and also newly
identify genes differentially expressed between MSCs and
FBs such as GDF5 (growth differentiation factor-5) and
HAPLN1 (hyaluronan and proteoglycan link protein 1),
which are involved in skeletal development, cartilage for-
mation, and maintenance [24,31]. Further to defining the
HN cells as MSCs, our transcriptional analysis indicates
that these MSCs share a gene-specific expression profile
more comparable to SF-MSCs. We compared HN- and
SF-MSCs not only with normal ICBM-MSCs but also with
BM from OA patients. For ethical reasons, OA BM could
not be collected from the iliac crest of these patients. Ra-
ther, MSCs were derived from two sources: (a) the medul-
lary canal of the femur and (b) trabecular bone of femoral
head from OA patients all undergoing hip arthroplasty.
We have previously described these MSCs as functional
and phenotypic indistinct from their ICBM counterparts
[15,16]. Such analysis allowed joint/BM-specific differ-
ences to be identified rather than differences relating to
OA. Among genes expressed by HN- and SF-MSCs (but
downregulated in BM-MSCs) were the recently identified
marker of synovium MSCs, SFPR4 [9], and several genes
known to be associated with cartilage formation and
maintenance, such as ACAN, BMP4, PRELP, and TNFIP6
(Figure 4 and Table 2) [22,24,31,32]. To fully confirm the
tissue origin of MSCs in vivo and to establish their migra-
tion patterns following injury or in disease, lineage tracing
experiments in animal models are required [33]. Never-
theless, our transcript data as well as previous findings
[27-30] indicate that broad tissue or niche-specific tran-
scriptional profiles are maintained in culture and as such
can be informative on the MSC ‘in vivo’ functionality in a
given environment.
With both normal human and animal joints having re-
sident SF-MSCs [17], it is possible that HN-MSCs are
entrapped from SF extruded through sites of weakness
in the joint capsule [34] and that, like the knee, small
joints contain a resident SF-MSC population. Previous
gene profile analysis indicates that SF-MSCs in turn ori-
ginate from the adjacent synovium [8,9], and our data
suggest a similar origin for HN-MSCs based on transcrip-
tional analysis. Our data cannot exclude the possibilitythat HN-MSCs are BM-derived but transcriptionally
‘altered’ following their entrance into the joint environ-
ment; this is, however, unlikely as no damage to bone and
hence the entry route for these MSCs can be identified at
this early stage of OA. We therefore conclude that, similar
to SF-MSCs, HN-MSCs are most likely of synovial origin.
Although HNs are forerunners of new bone formation, no
significant osteogenic bias was seen in any HN-MSC cul-
tures (either by qPCR or differentiation assay); this may be
explained by the fact that, in this study, HN material was
collected early in disease, prior to ossification. As such,
our data suggest that these MSCs are unlikely to have in-
trinsic osteogenic bias, perhaps with the aberrant new
bone formation seen in HNs a result of subsequent alter-
ations in joint biomechanics.
Conclusions
We present the first description of MSCs in a small joint
at a stage when cartilage damage is minimal (as seen by
x-ray; Figure 1A). Future clinical studies will be needed
to establish whether these MSCs are mere “bystanders”
or in fact contribute to the aberrant remodeling and sub-
sequent ossification seen during disease progression. Con-
versely, these MSCs may represent an intrinsic joint repair
process that is abolished by cyst entrapment and altered
biomechanics. The identification of MSCs within another
as-yet-unexplored synovial compartment is further indica-
tion that joint-specific MSCs may be important for joint
homeostasis [5,35]. Additional studies on the biology of
SF-MSCs and whether these cells contribute to spontan-
eous joint repair are critical. The presence of these resident
MSCs may also offer a distinct therapeutic advantage. Per-
haps it may be possible to control disease progression and
elicit effective joint repair by identifying patients earlier in
disease, and correcting the underlying biochemical or bio-
mechanical instability prior to ossification.
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